Scarica l'app Stockscreener
0.6073
3.73%
-0.0235
Dopo l'orario di chiusura:
.61
0.0027
+0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.6308
Aprire:
$0.6299
Volume 24 ore:
471.39K
Relative Volume:
0.18
Capitalizzazione di mercato:
$24.06M
Reddito:
$1.04M
Utile/perdita netta:
$-67.50M
Rapporto P/E:
-0.3159
EPS:
-1.9222
Flusso di cassa netto:
$-60.67M
1 W Prestazione:
-0.07%
1M Prestazione:
+20.11%
6M Prestazione:
-82.09%
1 anno Prestazione:
-77.67%
Intervallo 1D:
$0.5976
$0.63
Intervallo di 1 settimana:
$0.557
$0.6391
Portata 52W:
$0.43
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Nome
Vistagen Therapeutics Inc
Settore
Industria
Telefono
650-577-3600
Indirizzo
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.6073 | 24.06M | 1.04M | -67.50M | -60.67M | -1.9222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Downgrade | Maxim Group | Buy → Hold |
| 2025-12-17 | Downgrade | Stifel | Buy → Hold |
| 2025-12-17 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-07 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-07-22 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Iniziato | Robert W. Baird | Outperform |
| 2021-02-18 | Iniziato | Jefferies | Buy |
| 2021-01-04 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Iniziato | Maxim Group | Buy |
| 2018-02-08 | Reiterato | Chardan Capital Markets | Buy |
| 2017-03-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie
VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - GlobeNewswire Inc.
VTGN UPCOMING DEADLINE ON MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit (2026-03-14) - Seeking Alpha
VTGN DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors ... - Bluefield Daily Telegraph
VTGN DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages - GlobeNewswire
VTGN Shareholder Alert: Vistagen Therapeutics, Inc. - GlobeNewswire
2026-03-13 | VTGN DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Vistagen Therapeutics, Inc. Investors to Join the Class Action Lawsuit Today | NDAQ:VTGN | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesVTGN - Sahm
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - lelezard.com
Holzer & Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the Vistagen Therapeutics, Inc. Securities Class Action - marketscreener.com
Holzer & Holzer, LLC Reminds VTGN Investors of the March - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
VTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - ChartMill
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER - GlobeNewswire
VTGN SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - lelezard.com
Vistagen Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsVTGN - cnhinews.com
Layoff Tracker: Vistagen, Evotec, Reckitt Benckiser Downsize, Collectively Affecting Hundreds - BioSpace
Does Vistagen Therapeutics Inc. stock trade at a discount to peersForecast Cut & Reliable Price Action Trade Plans - mfd.ru
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, - GlobeNewswire
Vistagen Therapeutics, Inc. Files Form 8-K with SEC: Company Information, Stock Details, and Compliance Disclosures (March 2026) - Minichart
Aug Highlights: Will Vistagen Therapeutics Inc outperform during market ralliesIPO Watch & Long Hold Capital Preservation Tips - baoquankhu1.vn
Vistagen Therapeutics reduces workforce by 20 percent to manage costs - Investing.com South Africa
LEVI & KORSINSKY, LLP ADVISORY TO INSTITUTIONAL INVESTORS: CLASS ACTION AGAINST VISTAGEN THERAPEUTICS MAY IMPACT PORTFOLIO HOLDINGS - Morningstar
VistaGen Announces Workforce Reduction to Extend Cash Runway - TipRanks
Vistagen Therapeutics Implements 20% Workforce Reduction - TradingView
Vistagen Therapeutics cuts ~20% of workforce, expects PALISADE-4 topline H1 2026 and cash into 2027 - TradingView
VTGN DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages - GlobeNewswire
VTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline on March 16, 2026 - marketscreener.com
Contact The Gross Law Firm by March 16, 2026 Deadline to Join Class Action Against Vistagen Therapeutics, Inc.(VTGN) - PR Newswire
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors - GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Vistagen Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi ... - Bluefield Daily Telegraph
Vistagen Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Vistagen - GlobeNewswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
VTGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Vistagen (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - TMX Newsfile
VTGN (Vistagen Therapeutics) ROC (Joel Greenblatt) % : -5,196.68% (As of Dec. 2025) - GuruFocus
VTGN DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. ... - Bluefield Daily Telegraph
VTGN DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, - GlobeNewswire
VTGN (Vistagen Therapeutics) Shareholder Yield % : -128.43% (As of Dec. 2025) - GuruFocus
Vistagen Therapeutics (MEX:VTGN) Accounts Receivable : MXN0.00 Mil (As of Dec. 2025) - GuruFocus
VTGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline on March 16, 2026 - ACCESS Newswire
Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints - Sahm
Vistagen Therapeutics (MEX:VTGN) Graham Number : MXNN/A (As of Dec. 2025) - GuruFocus
Vistagen Therapeutics (MEX:VTGN) Beginning Cash Position : MXN1,130.51 Mil (As of Dec. 2025) - GuruFocus
Vistagen Therapeutics (MEX:VTGN) Other Income (Minority Int - GuruFocus
Vistagen Therapeutics Inc (MEX:VTGN) DCF Valuation - GuruFocus
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ... - Bluefield Daily Telegraph
2026-03-05 | VTGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Vistagen Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:VTGN | Press Release - Stockhouse
VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit - Barchart.com
VTGN DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
Vistagen Therapeutics Inc Azioni (VTGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):